Mettler-Toledo International (MTD) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 reported sales declined 5% year-over-year to $883.7 million, with local currency sales down 3%, but underlying growth in laboratory and process analytics was strong when excluding prior-year shipping delay recoveries.
Margin expansion strategies led to better-than-expected earnings despite global trade disputes and $115 million in annualized tariff costs, with mitigation actions underway.
Diverse product portfolio, agile operations, and continued investment in sales, marketing, and digital tools support resilience amid dynamic market conditions.
Service revenue grew 4% in USD and 6% in local currency, while product revenue declined 7% in USD and 6% in local currency.
Net earnings for the quarter were $163.6 million, with diluted EPS at $7.81.
Financial highlights
Q1 sales were $883.7 million, down 5% year-over-year; local currency sales down 3%, but up 3% excluding shipping delay recoveries.
Gross margin was 59.5%, up 30 bps year-over-year; adjusted operating profit was $236.7 million, down 11% year-over-year.
Adjusted EPS was $8.19, down 8% year-over-year; reported EPS was $7.81.
Adjusted free cash flow was $179.8 million, slightly down from $182.3 million in Q1 2024.
Operating cash flow was $194.4 million, up from $190.0 million in Q1 2024.
Outlook and guidance
Q2 2025 local currency sales expected to grow 0%-1%; adjusted EPS guidance: $9.45-$9.70, growth of -2% to +1%, with a net 3% EPS headwind from tariffs.
Full-year 2025 local currency sales growth forecast at 1%-2% (2.5%-3.5% excluding shipping delays); adjusted EPS expected at $41.25-$42, reflecting 0%-2% growth (4%-6% excluding shipping delays), with a net 2% EPS headwind from tariffs.
Free cash flow expected at $860 million and share repurchases at $875 million for 2025.
Management expects gross margin to be negatively impacted by escalating global trade tariffs for the remainder of 2025.
Mitigating actions are expected to fully offset tariff costs by next year.
Latest events from Mettler-Toledo International
- Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Adjusted EPS up 9% and sales up 7% in Q1 2026, with raised full-year EPS guidance.MTD
Q1 202614 May 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026 - Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026